Desmopressin
Also known as: DDAVP, 1-deamino-8-D-arginine vasopressin, Minirin, Stimate
A synthetic vasopressin analog that regulates water reabsorption and is used clinically for diabetes insipidus, nocturnal enuresis, and hemophilia management.
Research Status
FDA-approved
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Occurs when desmopressin-induced water reabsorption exceeds water intake, diluting serum sodium. Symptoms include headache, nausea, confusion, lethargy, seizures, and coma. Risk increases with excessive fluid intake, renal impairment, or SIADH. Requires immediate medical evaluation and serum sodium measurement. Fluid restriction is the primary management strategy.
Often mild and self-resolving. May be related to hyponatremia or local injection site effects. Monitor serum sodium if headaches persist or worsen.
Usually mild and transient. May occur within 1–2 hours of injection. Can be a sign of hyponatremia; monitor serum sodium if symptoms persist.
Mild gastrointestinal discomfort may occur, particularly with higher doses. Typically resolves within a few hours.
Transient facial flushing or warmth may occur due to mild vasodilation from V1 receptor activation. Self-resolving.
Mild erythema, swelling, or discomfort at the injection site. Prevented by proper site rotation and injection technique. Apply ice if needed.
Rare but possible; includes urticaria, angioedema, or anaphylaxis. Seek immediate medical attention if difficulty breathing, throat swelling, or severe rash occurs.
Severe hyponatremia with cerebral edema, seizures, and altered consciousness. Occurs with excessive desmopressin dosing and high fluid intake. Requires emergency medical intervention and fluid restriction.
Very rare; reported with high-dose desmopressin in patients with thrombotic risk factors. Monitor for signs of deep vein thrombosis or pulmonary embolism.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 10-20 mcg |
| Frequency | 1-2x daily |
| Timing | Evening for nocturnal enuresis; morning and evening for diabetes insipidus management |
| Route | Subcutaneous, Intranasal, Oral |
Subcutaneous dosing typically ranges 10–20 mcg per injection. Intranasal and oral formulations use different dosing. Start at lower end and titrate based on clinical response and serum sodium monitoring. For research purposes only.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 1069.2 |
| Half-life | 2.5 hours (subcutaneous); 1.5–2.5 hours (intranasal) |
| Sequence | H-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 |
Desmopressin is a synthetic analog of vasopressin (antidiuretic hormone) that selectively activates V2 receptors on the principal cells of the kidney's collecting duct. This activation increases aquaporin-2 water channel expression and insertion into the apical membrane, enhancing water reabsorption and reducing urine output. It also has weak V1 receptor activity, which contributes to hemostatic effects by promoting von Willebrand factor and factor VIII release from endothelial cells.
V2 Receptor Signaling (cAMP-PKA Pathway)
Desmopressin binds to V2 receptors on collecting duct principal cells, activating adenylyl cyclase via Gs proteins. This increases intracellular cAMP, activating protein kinase A (PKA), which phosphorylates aquaporin-2 channels and promotes their trafficking to the apical membrane. This increases water permeability and reabsorption, reducing urine output and increasing serum osmolality.
Hemostatic Effect (V1 Receptor-Mediated)
Weak V1 receptor activation on endothelial cells triggers phospholipase C signaling, increasing intracellular calcium and promoting the release of von Willebrand factor (vWF) and factor VIII from Weibel-Palade bodies. This improves platelet adhesion and coagulation, making desmopressin useful in hemophilia A and von Willebrand disease.
Aquaporin-2 Channel Upregulation
Chronic desmopressin exposure increases aquaporin-2 gene transcription and protein synthesis in collecting duct cells, enhancing the kidney's capacity for water reabsorption over time.
- Desmopressin is selective for V2 receptors at therapeutic doses, minimizing vasopressor effects seen with native vasopressin
- The 1-deamino modification at position 1 and D-arginine at position 8 increase metabolic stability and V2 selectivity compared to vasopressin
- Aquaporin-2 channels are the primary target; their phosphorylation and membrane trafficking directly determine antidiuretic efficacy
- Desmopressin does not cross the blood-brain barrier significantly, reducing central nervous system side effects
- Hyponatremia (low serum sodium) is the primary safety concern due to excessive water reabsorption; serum sodium monitoring is essential during therapy
Track your Desmopressin research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Desmopressin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.